No rationale for use of combination of quinolones and anti-protozoal agents for acute diarrhea in India

被引：0
|
作者：
Usha Dutta
机构：
[1] Postgraduate Institute of Medical Education and Research,Department of Gastroenterology
来源：
Indian Journal of Gastroenterology | 2009年 / 28卷 / 1期
关键词：
Diarrhea; Quinolones; Acute Diarrhea; Persistent Diarrhea; Large Market Share;
D O I：
10.1007/s12664-009-0012-5
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：38 / 38
相关论文
共 38 条
  • [21] Towards treatment planning of COVID-19: Rationale and hypothesis for the use of multiple immunosuppressive agents: Anti-antibodies, immunoglobulins, and corticosteroids
    Saghazadeh, Amene
    Rezaei, Nima
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2020, 84
  • [22] Hypomethylating agents in combination with venetoclax for acute myeloid leukemia: Update on clinical trial data and practical considerations for use
    Mei, Matthew
    Aldoss, Ibrahim
    Marcucci, Guido
    Pullarkat, Vinod
    AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (03) : 358 - 362
  • [23] Increasing the use of anti, inflammatory agents for acute asthma in the emergency department: Experience with an asthma care map
    Rowe, Brian H.
    Chahal, Anthony M.
    Spooner, Carol H.
    Blitz, Sandra
    Senthilselvan, Ambikaipakan
    Wilson, Deborah
    Holroyd, Brian R.
    Bullard, Michael
    CANADIAN RESPIRATORY JOURNAL, 2008, 15 (01) : 20 - 26
  • [24] Outcomes and Predictors of Relapse with Use of Hypomethylating Agents in Combination with Venetoclax Prior to Allogeneic Transplant in Acute Myeloid Leukemia
    Nizamuddin, Imran
    Oh, Timothy Seijung
    Numan, Yazan
    Kelsten, Max Farber
    Burkart, Madelyn
    Frankfurt, Olga
    Vigil, Carlos E.
    Abaza, Yasmin
    Altman, Jessica K.
    Dinner, Shira
    BLOOD, 2021, 138
  • [25] Use of venetoclax in combination with hypomethylating agents in patients with acute myeloid leukemia relapsing after allogeneic hematopoietic stem cell transplantation
    Ozturk, C.
    Sahin, U.
    Seval, G. C.
    Bozdag, S. C.
    Toprak, S. K.
    Yuksel, M. K.
    Topcuoglu, P.
    Ozcan, M.
    Gurman, G.
    Ilhan, O.
    Arslan, O.
    BONE MARROW TRANSPLANTATION, 2022, 57 (SUPPL 1) : 335 - 336
  • [26] The impact of previous use of anti platelet agents on hemorrhagic transformation in acute ischemic stroke post-thrombolytic therapy
    Mashayekhi, Mahboubeh
    Huynh, Susan
    Whittaker, Alana
    Decerbo, Mark
    Mccoy, Joseph
    PHARMACOTHERAPY, 2015, 35 (11): : E308 - E308
  • [27] Use of Nepafenac (Nevanac) in Combination With Intravitreal Anti-VEGF Agents in the Treatment of Recalcitrant Exudative Macular Degeneration Requiring Monthly Injections
    Chen, E.
    Benz, M. S.
    Fish, R. H.
    Brown, D. M.
    Wong, T. P.
    Kim, R. Y.
    Major, J. C.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2010, 51 (13)
  • [28] Use of nepafenac (Nevanac (R)) in combination with intravitreal anti-VEGF agents in the treatment of recalcitrant exudative macular degeneration requiring monthly injections
    Chen, Eric
    Benz, Matthew S.
    Fish, Richard H.
    Brown, David M.
    Wong, Tien P.
    Kim, Rosa Y.
    Major, James C.
    CLINICAL OPHTHALMOLOGY, 2010, 4 : 1249 - 1252
  • [29] EFFECTS OF HARRINGTONINE (HT) IN COMBINATION WITH VARIOUS ANTI-TUMOR AGENTS ON HUMAN ACUTE MYELOGENOUS LEUKEMIA-CELL LINE KG-1
    OKANO, T
    OHNUMA, T
    HOLLAND, JF
    GOLDBERG, AI
    KOEFFLER, HP
    JUI, H
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1983, 24 (MAR): : 271 - 271
  • [30] CI-994 (N-acetyl-dinaline) in combination with conventional anti-cancer agents is effective against acute myeloid leukemia in vitro and in vivo
    Hubeek, I.
    Comijn, E. M.
    Van der Wilt, C. L.
    Merriman, R. L.
    Padron, J. M.
    Kaspers, G. J. L.
    Peters, G. J.
    ONCOLOGY REPORTS, 2008, 19 (06) : 1517 - 1523
1234